Yoshikazu Hori

Dr. Yoshikazu Hori

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2024 in Hematology Reports
Verified
Journal Article
Open access
PDF file
YHYoshikazu Hori
Yoshikazu Hori
HHHiroki Hosoi
Hiroki Hosoi
THTakayuki Hiroi
Takayuki Hiroi
KWKe Wan
Ke Wan
SMShogo Murata
Shogo Murata
TSTakashi Sonoki
Takashi Sonoki
Background: Although the prognosis of follicular lymphoma (FL) has improved, some patients experience early disease progression, including progression of disease within 24 months (POD24). Histological transformation is a critical event in FL. However, the heterogeneity of FL tumors makes it challenging to diagnose transformation accurately. We retrospectively applied the clinical transformation criteria used for FL transformation assessments at relapse or disease progression to conduct transformation assessments before the initial immunochemotherapy. Methods: Sixty-six FL patients who first received immunochemotherapy between January 2009 and February 2023 at our institution were selected. Twenty-three were clinical-transformation-positive (CLT+). Results: The progression-free survival (PFS) rate of the CLT+ patients was significantly lower than that of the clinical-transformation-negative (CLT−) patients. In the POD24 assessment subgroup, the CLT+ patients had a higher incidence of POD24 than the CLT− patients. There was no significant difference in PFS between the patients treated with CHOP-like regimens and those treated with bendamustine regimens. In the CHOP-like group, the CLT+ patients exhibited significantly lower PFS than the CLT− patients. In the bendamustine group, the clinical transformation did not affect PFS. Conclusion: Clinical transformation criteria may be useful for the prognostic stratification of FL prior to immunochemotherapy. Additionally, they may serve as predictors of POD24.

7 February 2024 in Hematology Reports
Verified
Journal Article
Open access
PDF file
MMMasaya Morimoto
Masaya Morimoto
YYYuma Yokoya
Yuma Yokoya
KYKikuaki Yoshida
Kikuaki Yoshida
HKHideki Kosako
Hideki Kosako
YHYoshikazu Hori
Yoshikazu Hori
SOSachiko Ohde
Sachiko Ohde
Febrile neutropenia (FN) is a major concern in patients undergoing chemotherapy for diffuse large B-cell lymphoma (DLBCL); however, the overall risk of FN is difficult to assess. This study aimed to develop a model for predicting the occurrence of FN in patients with DLBCL. In this multicenter, retrospective, observational analysis, a multivariate logistic regression model was used to analyze the association between FN incidence and pretreatment clinical factors. We included adult inpatients and outpatients (aged ≥ 18 years) diagnosed with DLBCL who were treated with chemotherapy. The study examined 246 patients. Considering FN occurring during the first cycle of chemotherapy as the primary outcome, a predictive model with a total score of 5 points was constructed as follows: 1 point each for a positive hepatitis panel, extranodal involvement, and a high level of soluble interleukin-2 receptor and 2 points for lymphopenia. The area under the receiver operating characteristic curve of this model was 0.844 (95% confidence interval: 0.777–0.911). Our predictive model can assess the risk of FN before patients with DLBCL start chemotherapy, leading to better outcomes.

15 October 2025 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
YHYoshikazu Hori
Yoshikazu Hori
HHHiroki Hosoi
Hiroki Hosoi
MOMitsuo Osuga
Mitsuo Osuga
RIRyuta Iwamoto
Ryuta Iwamoto
FMFumiyo Maekawa
Fumiyo Maekawa
STSonoki Takashi
Sonoki Takashi
Early disease progression, including histological transformation, can occur in follicular lymphoma, but tumor heterogeneity makes comparison difficult. We analyzed cell-free DNA from 30 patients with follicular lymphoma to assess cell-free DNA concentration and gene mutations. Mutational profiles were also examined in 16 cases using DNA from formalin-fixed, paraffin-embedded tissue samples. Cell-free DNA concentrations were higher in cases with histological transformation. Both the number of mutations per patient and the number of mutated genes were greater in cell-free DNA than in formalin-fixed, paraffin-embedded tissue-derived DNA. Notably, TP53 mutations were more frequently detected in cell-free DNA. CIITA mutations were more commonly observed in cases with a low frequency of somatic hypermutation in VH genes. Cell-free DNA analysis in follicular lymphoma may become a complementary approach, overcoming the limitations of assessing disease status from single biopsy sites. Further studies will examine the usefulness of cell-free DNA in predicting disease progression in follicular lymphoma.

3 February 2026 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
KYKikuaki Yoshida
Kikuaki Yoshida
TMToshiki Mushino
Toshiki Mushino
KTKen Tanaka
Ken Tanaka
HKHideki Kosako
Hideki Kosako
YHYoshikazu Hori
Yoshikazu Hori
HHHiroki Hosoi
Hiroki Hosoi

2 November 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
MMMasaya Morimoto
Masaya Morimoto
YYYuma Yokoya
Yuma Yokoya
KYKikuaki Yoshida
Kikuaki Yoshida
HKHideki Kosako
Hideki Kosako
YHYoshikazu Hori
Yoshikazu Hori
SOSachiko Ohde
Sachiko Ohde
Febrile neutropenia (FN) is a major concern in patients undergoing chemotherapy for diffuse large B-cell lymphoma (DLBCL); however, the overall risk of FN is difficult to assess. This study aimed to develop a model for predicting the occurrence of FN in patients with DLBCL. In this multicenter, retrospective, observational analysis, a multivariate logistic regression model was used to analyze the association between FN incidence and pretreatment clinical factors. We included adult inpatients and outpatients (aged ≥ 18 years) diagnosed with DLBCL who were treated with chemotherapy. The study examined 246 patients. Considering FN occurring during the first cycle of chemotherapy as the primary outcome, a predictive model with a total score of 5 points was constructed as follows: 1 point each for viral hepatitis, extranodal involvement, and a high level of soluble interleukin-2 receptor and 2 points for lymphopenia. The area under the receiver operating characteristic curve of this model was 0.844 (95% confidence interval: 0.777–0.911). Our predictive model can assess the risk of FN before patients with DLBCL start chemotherapy, leading to better outcomes.